Advertisement

Pediatric Drugs

, Volume 20, Issue 5, pp 475–481 | Cite as

Efficacy and Safety of Intravenous Colistin in Very Low Birth Weight Preterm Infants

  • Ozkan IlhanEmail author
  • Meltem Bor
  • Senem Alkan Ozdemir
  • Sinem Akbay
  • Esra Arun Ozer
Original Research Article

Abstract

Background

Given the severity and high mortality of multidrug-resistant Gram-negative bacilli (MDR-GNB) infections, the use of colistin will increase in patients with MDR-GNB infection.

Objective

This study aims to assess the efficacy and safety of intravenous colistin in very low birth weight (VLBW; birth weight < 1500 g) preterm infants.

Methods

We retrospectively analyzed the medical records of patients who received colistin between June 2016 and December 2017. The patients were assigned to two groups: the VLBW group and the non-VLBW group. Both groups were evaluated for response to treatment and adverse effects.

Results

In total, 66 infants who received colistin therapy were included; of these, 28 infants were VLBW. All of our patients received standard colistin treatment of 5 mg/kg per day in three doses and the median duration of colistin treatment was 14 days. No significant differences were observed between the groups with respect to the efficacy of colistin (defined as showing microbiological clearance in control cultures and the absence of mortality during treatment) (89.3 vs 86.8%, p > 0.99). Serum magnesium and potassium levels were significantly lower in the VLBW group than in the non-VLBW group during colistin therapy (magnesium, 1.30 vs 1.70 mg/dL, p < 0.001; potassium, 3.6 vs 4.6 mEq/L, p < 0.001). Acute kidney injury was observed in four infants in the VLBW group and one in the non-VLBW group, without significant differences (p = 0.15).

Conclusions

Colistin administration appears to be efficacious in VLBW infants; however, renal function tests and serum electrolytes should be monitored more closely in these infants during treatment.

Notes

Compliance with Ethical Standards

Funding

This study did not receive any specific funding.

Conflict of interest

Ozkan Ilhan, Meltem Bor, Senem Alkan Ozdemir, Sinem Akbay and Esra Arun Ozer have no conflicts of interest to declare.

References

  1. 1.
    Aly H, Herson V, Duncan A, Herr J, Bender J, Patel K, et al. Is bloodstream infection preventable among premature infants? A tale of two cities. Pediatrics. 2005;115:1513–8.CrossRefPubMedGoogle Scholar
  2. 2.
    Stoll BJ, Hansen N, Fanaroff AA, Wright LL, Carlo WA, Ehrenkranz RA, et al. Late-onset sepsis in very low birth weight neonates: the experience of the NICHD Neonatal Research Network. Pediatrics. 2002;110:285–91.CrossRefPubMedGoogle Scholar
  3. 3.
    Karaiskos I, Galani L, Baziaka F, Giamarellou H. Intraventricular and intrathecal colistin as the last therapeutic resort for the treatment of multidrug-resistant and extensively drug-resistant Acinetobacter baumannii ventriculitis and meningitis: a litera-ture review. Int J Antimicrob Agents. 2013;41:499–508.CrossRefPubMedGoogle Scholar
  4. 4.
    Lee HY, Chiu CH. Efficacy and safety of using colistin in neonates. Pediatr Neonatol. 2017;58:473–4.CrossRefPubMedGoogle Scholar
  5. 5.
    Koch-Weser J, Sidel VW, Federman EB, Kanarek P, Finer DC, Eaton AE. Adverse effects of sodium colistimethate. Manifestations and specific reaction rates during 317 courses of therapy. Ann Intern Med. 1970;72:857–68.CrossRefPubMedGoogle Scholar
  6. 6.
    Cagan E, Kıray Bas E, Asker HS. Use of colistin in a neonatal ıntensive care unit: a cohort study of 65 patients. Med Sci Monit. 2017;23:548–54.CrossRefPubMedPubMedCentralGoogle Scholar
  7. 7.
    Falagas ME, Vouloumanou EK, Rafailidis PI. Systemic colistin use in children without cystic fibrosis: a systematic review of the literature. Int J Antimicrob Agents. 2009;33(503):e1–13.Google Scholar
  8. 8.
    Iosifidis E, Antachopoulos C, Ioannidou M, Mitroudi M, Sdougka M, Drossou-Agakidou V, et al. Colistin administration to pediatric and neonatal patients. Eur J Pediatr. 2010;169:867–74.CrossRefPubMedGoogle Scholar
  9. 9.
    Alan S, Yildiz D, Erdeve O, Cakir U, Kahvecioglu D, Okulu E, et al. Efficacy and safety of intravenous colistin in preterm infants with nosocomial sepsis caused by Acinetobacter baumannii. Am J Perinatol. 2014;31:1079–86.CrossRefPubMedGoogle Scholar
  10. 10.
    Jetton JG, Askenazi DJ. Update on acute kidney injury in the neonate. Curr Opin Pediatr. 2012;24:191–6.CrossRefPubMedPubMedCentralGoogle Scholar
  11. 11.
    Horan TC, Andrus M, Dudeck MA. CDC/NHSN surveillance definition of health care-associated infection and criteria for specific types of infections in the acute care setting. Am J Infect Control. 2008;36:309–32.CrossRefPubMedGoogle Scholar
  12. 12.
    İpek MS, Aktar F, Okur N, Celik M, Ozbek E. Colistin use in critically ill neonates: a case-control study. Pediatr Neonatol. 2017;58:490–6.CrossRefPubMedGoogle Scholar
  13. 13.
    Jajoo M, Kumar V, Jain M, Kumari S, Manchanda V. Intravenous colistin administration in neonates. Pediatr Infect Dis J. 2011;30:218–21.CrossRefPubMedGoogle Scholar
  14. 14.
    Jasani B, Kannan S, Nanavati R, Gogtay NJ, Thatte U. An audit of colistinuse in neonatal sepsis from a tertiary care centre of a resource-limited country. Indian J Med Res. 2016;144:433–9.CrossRefPubMedPubMedCentralGoogle Scholar
  15. 15.
    Nag SS, Dutta A, Mitra P, Majumdar R, Chatterjee M. Intravenous colistimethate sodium in neonatal sepsis. Indian J Pediatr. 2016;83:864–5.CrossRefPubMedGoogle Scholar
  16. 16.
    Al-Lawama M, Aljbour H, Tanash A, Badran E. Efficacy and safety of intravenous colistin in preterm infants with nosocomial sepsis caused by Acinetobacter baumannii. Ann Clin Microbiol Antimicrob. 2016;15:8.CrossRefPubMedPubMedCentralGoogle Scholar
  17. 17.
    Serafettin Tekgunduz K, Kara M, Caner I, Demirelli Y. Safety and efficacy of intravenous colistin in neonates with culture proven sepsis. Iran J Pediatr. 2015;25:e453.CrossRefPubMedPubMedCentralGoogle Scholar
  18. 18.
    Choudhry S, Ahmad E, Batool A, Raja N. Use of colistin for the treatment of multi drug resistant isolates in neonates. J Pak Med Assoc. 2017;67:1157–60.PubMedGoogle Scholar
  19. 19.
    Lewis JR, Lewis SA. Colistin interactions with the mammalian urothelium. Am J Physiol Cell Physiol. 2004;286:913–22.CrossRefGoogle Scholar
  20. 20.
    Berg JR, Spilker CM, Lewis SA. Effects of polymyxin B on mammalian urinary bladder. J Membr Biol. 1996;154(2):119–30.CrossRefPubMedGoogle Scholar
  21. 21.
    Mackenzie HS, Brenner BM. Fewer nephrons at birth: a missing link in the etiology of essential hypertension? Am J Kidney Dis. 1995;26:91–8.CrossRefPubMedGoogle Scholar
  22. 22.
    Stritzke A, Thomas S, Amin H, Fusch C, Lodha A. Renal consequences of preterm birth. Mol Cell Pediatr. 2017;4:2.CrossRefPubMedPubMedCentralGoogle Scholar
  23. 23.
    Rhone ET, Carmody JB, Swanson JR, Charlton JR. Nephrotoxic medication exposure in very low birth weight infants. J Matern Fetal Neonatal Med. 2014;27:1485–90.CrossRefGoogle Scholar
  24. 24.
    Schreuder MF, Bueters RR, Allegaert K. The interplay between drugs and the kidney in premature neonates. Pediatr Nephrol. 2014;29:2083–91.CrossRefGoogle Scholar
  25. 25.
    Pogue JM, Lee J, Marchaim D, Yee V, Zhao JJ, Chopra T, et al. Incidence of and risk factors for colistin associated nephrotoxicity in a large academic health system. Clin Infect Dis. 2011;53:879–84.CrossRefPubMedGoogle Scholar
  26. 26.
    Spapen H, Jacobs R, Van Gorp V, Troubleyn J, Honoré PM. Renal and neurological side effects of colistin in critically ill patients. Ann Intensive Care. 2011;1:14.CrossRefPubMedPubMedCentralGoogle Scholar

Copyright information

© Springer Nature Switzerland AG 2018

Authors and Affiliations

  1. 1.Department of NeonatologyHarran University Faculty of MedicineSanliurfaTurkey
  2. 2.Department of NeonatologyBehcet Uz Children’s HospitalIzmirTurkey
  3. 3.Department of NeonatologyTokat State HospitalTokatTurkey
  4. 4.Department of NeonatologyCelal Bayar University Faculty of MedicineManisaTurkey

Personalised recommendations